|
|
Volumn 377, Issue 15, 2017, Pages 1409-1412
|
|
First FDA approval agnostic of cancer site — When a biomarker defines the indication
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PEMBROLIZUMAB;
ANTINEOPLASTIC AGENT;
CD274 PROTEIN, HUMAN;
MONOCLONAL ANTIBODY;
PDCD1 PROTEIN, HUMAN;
PROGRAMMED DEATH 1 LIGAND 1;
PROGRAMMED DEATH 1 RECEPTOR;
TUMOR MARKER;
BILE DUCT CANCER;
BILE DUCT CARCINOMA;
BREAST CANCER;
CANCER LOCALIZATION;
CANCER PROGNOSIS;
CANCER RECURRENCE;
CANCER REGISTRY;
CANCER STAGING;
COLITIS;
COLORECTAL CANCER;
DRUG APPROVAL;
DRUG SAFETY;
ENDOCRINE DISEASE;
ENDOMETRIUM CANCER;
ESOPHAGUS CANCER;
FOOD AND DRUG ADMINISTRATION;
GENE MUTATION;
HEPATITIS;
HISTOLOGY;
HUMAN;
MICROSATELLITE INSTABILITY;
MISMATCH REPAIR;
NEPHRITIS;
NON SMALL CELL LUNG CANCER;
OVERALL SURVIVAL;
PANCREAS CANCER;
PNEUMONIA;
PRIORITY JOURNAL;
PROSTATE CANCER;
SHORT SURVEY;
SMALL INTESTINE CANCER;
STOMACH CANCER;
TREATMENT DURATION;
TREATMENT INDICATION;
TREATMENT RESPONSE;
ADULT;
ANTAGONISTS AND INHIBITORS;
BRAIN NEOPLASMS;
BREAST NEOPLASMS;
CHILD;
COLORECTAL NEOPLASMS;
DIGESTIVE SYSTEM NEOPLASMS;
FEMALE;
MALE;
METABOLISM;
NEOPLASM METASTASIS;
NEOPLASTIC SYNDROMES, HEREDITARY;
PATHOLOGY;
UNITED STATES;
UROGENITAL NEOPLASMS;
ADULT;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTIGENS, CD274;
ANTINEOPLASTIC AGENTS;
BIOMARKERS, TUMOR;
BRAIN NEOPLASMS;
BREAST NEOPLASMS;
CHILD;
COLORECTAL NEOPLASMS;
DIGESTIVE SYSTEM NEOPLASMS;
DRUG APPROVAL;
FEMALE;
HUMANS;
MALE;
MICROSATELLITE INSTABILITY;
NEOPLASM METASTASIS;
NEOPLASTIC SYNDROMES, HEREDITARY;
PROGRAMMED CELL DEATH 1 RECEPTOR;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
UROGENITAL NEOPLASMS;
|
|
EID: 85031043375
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMp1709968 Document Type: Short Survey |
|
Times cited : (537)
|
|
References (5)
|
